Semaglutide is a prescription medication that is legal in the United States when prescribed by a healthcare provider. It is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. The medication is available under the brand names Ozempic (injectable) and Rybelsus (oral).

The U.S. Food and Drug Administration (FDA) approved Ozempic in 2017 and Rybelsus in 2019 for the treatment of type 2 diabetes in conjunction with diet and exercise. Additionally, the FDA has approved Ozempic for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is important to note that semaglutide is not for the treatment of type 1 diabetes or diabetic ketoacidosis.

For more details on ozempic legality in US, visit legalitylens.com